Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
pharma · Narcolepsy and Idiopathic Hypersomnia · Narcolepsy Type 1 · CNTA
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB HQ
2021 Founded
142 Employees
Public company Type
CNTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB
- Founded
- 2021
- Employees
- 142
- Programs
- 15
- Drugs
- 11
- Patents
- 7
Centessa Pharmaceuticals pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Centessa Pharmaceuticals drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Centessa Pharmaceuticals in public FDA and regional records.